key: cord-0697323-91qtcvsz
authors: Karakoc Aydiner, Elif; Bilgic Eltan, Sevgi; Babayeva, Royale; Aydiner, Omer; Kepenekli, Eda; Kolukisa, Burcu; Sefer, Asena Pinar; Yalcin Gungoren, Ezgi; Karabiber, Esra; Yucel, Esra Ozek; Ozdemir, Oner; Kiykim, Ayca; Artac, Hasibe; Yakici, Nalan; Yalcin, Koray; Cokugras, Haluk; Celkan, Tulin Tiraje; Orhan, Fazil; Yesilipek, Mehmet Akif; Baris, Safa; Ozen, Ahmet
title: Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses
date: 2021-08-10
journal: Allergy
DOI: 10.1111/all.15025
sha: 85aa5ae25bf1de7db214ac0acbd94fa5e3e87910
doc_id: 697323
cord_uid: 91qtcvsz

BACKGROUND: Genetic deficiencies of immune system, referred to as inborn errors of immunity (IEI), serve as a valuable model to study human immune responses. In a multicenter prospective cohort, we evaluated the outcome of SARS‐CoV‐2 infection among IEI subjects and analyzed genetic and immune characteristics that determine adverse COVID‐19 outcomes. METHODS: We studied 34 IEI patients (19M/15F, 12 [min: 0.6‐max: 43] years) from six centers. We diagnosed COVID‐19 infection by finding a positive SARS‐CoV‐2 PCR test (n = 25) and/or a lung tomography scoring (CORADS) ≥4 (n = 9). We recorded clinical and laboratory findings prospectively, fitted survival curves, and calculated fatality rates for the entire group and each IEI subclass. RESULTS: Nineteen patients had combined immune deficiency (CID), six with predominantly antibody deficiency (PAD), six immune dysregulation (ID), two innate immune defects, and one in the autoinflammatory class. Overall, 23.5% of cases died, with disproportionate fatality rates among different IEI categories. PAD group had a relatively favorable outcome at any age, but CIDs and IDs were particularly vulnerable. At admission, presence of dyspnea was an independent risk for COVID‐related death (OR: 2.630, 95% CI; 1.198–5.776, p < .001). Concerning predictive roles of laboratory markers at admission, deceased subjects compared to survived had significantly higher CRP, procalcitonin, Troponin‐T, ferritin, and total‐lung‐score (p = .020, p = .003, p = .014, p = .013, p = .020; respectively), and lower absolute lymphocyte count, albumin, and trough IgG (p = .012, p = .022, p = .011; respectively). CONCLUSION: Our data disclose a highly vulnerable IEI subgroup particularly disadvantaged for COVID‐19 despite their youth. Future studies should address this vulnerability and consider giving priority to these subjects in SARS‐Cov‐2 therapy trials.

In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus, emerged in Hubei (China) as a novel human pathogen causing coronavirus disease 2019 (COVID-19) 1-3 with global spreading that led to a tragic pandemic. The spectrum of the infection is broad, ranging from asymptomatic illness to severe outcomes, including death. Symptomatic cases may experience diverse symptoms, including respiratory collapse, myocarditis, and thromboembolism, culminating in a fatal multiorgan failure syndrome. 4 During the time of this study, the case fatality rate of SARS-CoV-2 infection has ranged from 1% to 20%, compared to a disease fatality rate between 0.2% and 1.3% among the general population. 5 Epidemiologic data impart certain disadvantaged groups, who mainly stratified by age (each decade of life beyond age 50 years multiplying the risk), pre-existing comorbidities, Results: Nineteen patients had combined immune deficiency (CID), six with predominantly antibody deficiency (PAD), six immune dysregulation (ID), two innate immune defects, and one in the autoinflammatory class. Overall, 23.5% of cases died, with disproportionate fatality rates among different IEI categories. PAD group had a relatively favorable outcome at any age, but CIDs and IDs were particularly vulnerable.

At admission, presence of dyspnea was an independent risk for COVID-related death (OR: 2.630, 95% CI; 1.198-5.776 , p < .001). Concerning predictive roles of laboratory markers at admission, deceased subjects compared to survived had significantly higher CRP, procalcitonin, Troponin-T, ferritin, and total-lung-score (p = .020, p = .003, p = .014, p = .013, p = .020; respectively), and lower absolute lymphocyte count, albumin, and trough IgG (p = .012, p = .022, p = .011; respectively).

Our data disclose a highly vulnerable IEI subgroup particularly disadvantaged for COVID-19 despite their youth. Future studies should address this vulnerability and consider giving priority to these subjects in SARS-Cov-2 therapy trials.

COVID-19, inborn errors of immunity, outcome, SARS-Cov-2 G R A P H I C A L A B S T R A C T 34 IEI patients aged between 0.6 and 43 years, eight patients (23.5%) succumbed to COVID-19, indicating a highly vulnerable condition to COVID-19. Laboratory markers associated with mortality included elevated acute phase reactants, ferritin, troponin T, TLS, and reduced ALC levels, albumin, and baseline IgG. Coughing, dyspnea, CORADS category 4-6, and negative SARS-CoV-2 PCR at admission were among the predictors of lethal outcome. sex (male under higher risk), and genetic background. 5, 6 Interestingly, the course of COVID-19 among children significantly deviates from the general population for unexplained reasons, with substantially lower mortality rates than adults.

Deficiencies of the immune system, called inborn errors of immunity (IEI), disable host defense against pathogens and cause untoward inflammatory responses that disrupt self-tissues. Over 450 gene defects, categorized under ten different functional categories, have been linked to IEIs, with each harboring distinct and overlapping features. 7, 8 Whereas the most severe IEI forms profoundly impair immune protection against a diverse range of pathogens, certain IEIs create a predisposition to a narrow spectrum of pathogens, even a single microorganism. For example, defective CD27-CD70 axis produces EBV susceptibility in the affected host, and EVER1/EVER2 mutations lead to uncontrolled HPV infections; individuals with both conditions can handle broader infectious pathogens without detrimental health outcomes. 9 A recent survey showed that patients (aged 17-77 years) with immune defects affecting the TLR3-and IRF7-dependent type I interferon (IFN) production are predisposed to lethal SARS-CoV-2 infection. 6 The complexity of COVID-19 pathogenesis, that is, multiple system involvement and different inflammatory features, suggests that a breach in other signaling pathways may also create a vulnerability to this virus. Since the spread of infection across the world, researchers from different locations reported on COVID-19 outcomes among IEI individuals. [10] [11] [12] [13] Although the accumulating evidence contributes to our understanding of COVID-19 among IEI subjects, the studies report disparate results, mainly because of an assortment bias due to the differences in these disorders' geographic distribution. For example, IEIs that follow an autosomal recessive inheritance are relatively more common in the Middle East and North African countries and Turkey than in Western F I G U R E 1 Distribution of IEI categories and the probability of survival following COVID-19. (A) A pie-chart displays of the IEI categories and corresponding subclasses of the study group. AED-ID: anhidrotic ectodermal dysplasia-immune dysregulation, AGAM, agammaglobulinemia; AUTOINF, autoinflammatory; CID, combined immunodeficiency; CMC, chronic mucocutaneous candidiasis; CVID, common variable immunodeficiency; CORADS, COVID-19 Reporting SCID  SCID  CID  CID  CID  CID  CID  CID  CID  CID  CID   Sub-phenotype SCID  SCID  SyCID  SyCID  DNARD  DNARD  DNARD  NA  NA  HIGM  AED-ID   Genotype  IL− 

This study is a prospective survey that examined the outcome of 

We calculated the median and interquartile range values for con- 

We found that among 34 IEI patients enrolled, the predominant category was combined immune deficiencies (CID) (19 patients), among which three were classified as severe CID (SCID). Six patients were categorized under predominantly antibody deficiency (PAD), six with immune dysregulation (ID), two with innate immune deficiency, and one with an autoinflammatory syndrome. The distribution of IEI categories and the molecular diagnoses are presented in Figure 1A and Tables 1 and 2 was 44.4% (p = .003) ( Figure 1C ).

The frequencies of each presenting symptom were as follows: fever 67.5% (n = 23); coughing 50% (n = 17); dyspnea 32.4% (n = 11); fa- Figure 2A .

Laboratory data, including complete blood count, acute phase reactants, lactate, LDH, albumin, ferritin, d-dimer, and troponin T, are presented in Table S1 . Deceased patients tended to have a higher value of ANC and lower eosinophil and monocyte counts, despite without a statistically significant difference ( Figure 3A -C). The distribution of abnormal laboratory assessments concerning survival outcomes is presented in Figure 2A .

The distribution of CORADS (applicable for 58.8% patients, n = 20) was as follows: category-1 5% (n = 1), category-2 5% (n = 1); category-3 15% (n = 3); category-4 20% (n = 4); category-5 45% (n = 9); and category-6 10% (n = 2). Thus, 15 patients had a CORADS score of ≥4, the range considered being highly suggestive of COVID-19. The median TLS for the overall cohort was 5 (min=0 and max =20). Interestingly, TLS was significantly lower among patients who survived COVID-19 as compared to those who succumbed to the infection ( Figure 2H ).

We investigated the clinical parameters associated with a relatively more severe course of COVID-19; we considered "requirement for inpatient care" as a surrogate marker for this analysis. When evaluating the laboratory tests at admission, patients were cared for as inpatient vs. those followed as outpatients had comparatively lower values of ALC and albumin (p = .010 and p = .019, respectively), and higher levels of CRP, PcT, and troponin T (p < .001, p = .038, and p = .014, respectively) (Table S2) . A similar analysis inquiring risk factors for a need for ICU care (n = 8) indicated that lower levels of ALC and albumin (p = .012 and p = .022, respectively) and higher values of CRP, PcT, ferritin, troponin T, and TLS (p = .020, p = .003, p = .013, p = .003, and p = .020, respectively) were key biomarkers (Table S3) .

A more detailed analysis in these cases revealed a progressive de- 

KARAKOC AYDINER Et Al. In the entire cohort, the infection fatality rate was 0.24 (8/34), the case fatality rate was 0.29 (8/28), as compared to an inpatient mortality rate of 0.34 (Table S4 ). In a subgroup analysis in which inpatient mortality was assessed, the highest mortality was if any, and only one patient received corticosteroid therapy. While we were unable to assess the corticosteroid response due to small sample size, we observed no meaningful impact of the immunomodulatory IVIG use on COVID-19 outcomes; the clinical, laboratory, and immunological parameters were comparable between the subjects who received this therapy with those of non-recipients.

One patient (P13) receiving convalescent plasma therapy and survived the infection. One patient (P29), who is among the deceased subjects, received extracorporeal membrane oxygenation and plasmapheresis.

We found that patients who succumbed to COVID-19 compared to Table S1 and Figure 3D -I. CD3 + T-cell counts and recent thymic emigrant (RTE) percentages were significantly lower in patients who required inpatient care compared to those followed as outpatients (Table S2) , and subjects who required ICU care had lower serum IgG levels compared to those who did not (Table S3 ).

We found that among 34 IEI patients aged between 0.6 and 43 years, eight patients (23.5%) succumbed to COVID-19, indicating IEI should be considered a highly vulnerable condition to COVID-19

irrespective of age. Laboratory markers associated with mortality included elevated acute phase reactants, ferritin, troponin T, TLS, and reduced ALC levels, serum albumin, and baseline IgG. The presence of coughing and dyspnea at presentation, CORADS category between 4 and 6, and negative SARS-CoV-2 PCR at admission were among the predictors of a lethal outcome. We also noted that among those who succumbed to COVID, there were longitudinal trends in Although it has been more than a year since the first inception of the COVID-19 pandemic, data on IEI patients' performance during this infection is scarce, with disparate reports indicating a relative mortality risk equaling to or ten times greater than the general population. 20 Our data showed a mortality rate of 23.5%, which is ×10 and ×23.5 higher than the global population 21 after developing symptoms. 23 The leading symptoms at admission in our cohort were fever, coughing, and dyspnea; these manifestations are similar to those reported in other cohorts. 11, 13, 24 It is interesting to note that we detected a positive SARS-CoV-2 PCR in 73.5% of cases; the remaining 26.5% received a COVID-19 diagnosis based on clinical grounds despite a negative PCR; namely, they had pneumonia and a CORADS score of ≥4. It is established that a PCR test's sensitivity for COVID-19 diagnosis is variable and subject to sample acquisition timing. Due to this limitation, clinical algorithms were developed to recognize COVID-19; a chest tomography scoring system (CORADS) 17 and TLS were proposed as valuable tests to assess the severity and extent of COVID-19 infection. 18 Hence, it is likely that those patients with a negative PCR at the time of presentation had an advanced stage of infection when the viral particles were cleared from the upper respiratory tract and localized to the lower compartments. This may explain why patients proved negative for a PCR test on nasopharyngeal swabs despite the typical clinical and radiologic findings of COVID-19. We propose that a probable COVID-19 diagnosis may be ruled in IEI subjects in the presence of clinically relevant respiratory findings, despite a lack of PCR evidence or absence of clear contact history. Serological tests for COVID-19 were assessed in a minority of IEIs patients. 12, 24 However, it should be recalled that IEI subjects may not establish SARS-CoV-2 antibodies because of their inability to mount specific humoral immune responses;

hence, serologic tests rely on an individual's antibody-production capacity may not be helpful in this context. and non-invasive ventilation, and immunoglobulins or convalescent plasma had been trialed with the variable outcome. 13, 25 In our cohort, similar strategies were employed, unfortunately, with no dramatic change in the outcome.

In conclusion, IEIs patients, when contracting COVID-19, are at least ten times higher risk for the deadly outcome than the global population. We and others show that PAD has a relatively more favorable outcome at any age, but CIDs and ID are particularly vulnerable.

Herein, we define a set of clinical markers that show poor COVID-19

outcomes; these predictors could be readily employed in the management of IEI subjects and further explored in future studies. We propose IEIs should be considered among COVID-19 disadvantaged groups irrespective of age. COVID-19 vaccines may protect a subgroup of IEIs, but unlikely to benefit those who cannot develop active immunity. There is an urgent need for studies exploring the role of specific therapies for IEIs, esp. those subtypes that are particularly susceptible to the infection. For example, a specific antibody cocktail may be trialed to provide passive immunity. The set of risk factors that we define can select patients who would be prioritized for preemptive therapies.

Authors would like to acknowledge the memory of the primary immune deficiency patients who passed away due to COVID-19

pandemic.

COVID-19) pandemic

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

A novel coronavirus from patients with pneumonia in China

Clinical and immunological features of severe and moderate coronavirus disease 2019

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification

Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee

Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency

COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience

Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel

Coronavirus disease 2019 in patients with inborn errors of immunity: an international study

Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic

Sağlık Bakanlığı COVID-19 Rehberi

World Health Organization (WHO) Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation

Predictive value of chest CT scoring in COVID-19 patients in Wuhan, China: a retrospective cohort study

False-negative results of initial RT-PCR assays for COVID-19: a systematic review

Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency

COVID-19) dashboard

Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City

Coronavirus disease 2019 (COVID-19): diagnosis and management

Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses